title: Sexual dysfunction in males with hepatitis C virus: relevance to histopathologic changes and peginterferon treatment.
abstract: OBJECTIVE
  The frequency of sexual dysfunction (SD) is not well known in patients with chronic hepatitis C virus (HCV). In spite of the fact that histological benefits of peginterferon (Peg-IFN)/ribavirin therapy are well established, the effects on sexual health are less certain. To assess the prevalence of the SD and explore its relevance to histopathologic changes and Peg-IFN treatment.
  
  
  METHODS
  The study included 100 HCV males; all the patients completed questionnaires to assess their sexual function before and during the treatment.
  
  
  RESULTS
  Before treatment, SD was reported only by 12 (19.4%) and 10 (29.4%) patients of early and advanced liver fibrosis, respectively. SD during HCV treatment (with Peg-IFN and ribavirin) for liver fibrosis was significant, as 24 (70.6%) out of 34 (100%) of HCV patients had advanced fibrosis but only 20 (32.3%) out of 62 (100%) patients had early fibrosis and were sexually affected (P = 0.01). SD before treatment was found in 22 (22%) patients; 16 (16%) were > 40 years old and 6 (6%) patients were ≤ 40 years old. SD showed highly significant (P = 0.001) difference prior to and during treatment. Pre treatment, 78 (78%) patients denied any SD and only 22 (22%) were sexually affected, while during treatment, the number of patients who were sexually affected rose to 44 (44%). The rest of the group [56 (56%)] did not report any sexual impairment.
  
  
  CONCLUSIONS
  SD was noticed during Peg-IFN and ribavirin treatment in patients with advanced liver fibrosis. Age and advanced liver fibrosis were important factors in inducing SD. This is of key importance for clinical practice as it modifies the management of HCV patients.
authors: Department of General Medicine, National Hepatology and Tropical Medicine Research Institute, Egypt. kamal245@homail.com
authors: Kamal A
authors: KA
authors: El-Atrebi
authors: Mohamed A
authors: MA
authors: El-Atrebi
authors: Hala T
authors: HT
authors: El-Bassyouni
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D001707:Biopsy, Needle; D004337:Drug Carriers; D004534:Egypt / Q000453:epidemiology; D005500:Follow-Up Studies; D016174:Hepacivirus / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification*; D018937:Hepatitis C Antibodies / Q000032:analysis; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D015994:Incidence; D016898:Interferon-alpha / Q000627:therapeutic use*; D008099:Liver / Q000473:pathology* / Q000821:virology; D008297:Male; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D015995:Prevalence; D011379:Prognosis; D011446:Prospective Studies; D012367:RNA, Viral / Q000032:analysis; D011994:Recombinant Proteins / Q000627:therapeutic use; D012735:Sexual Dysfunction, Physiological / Q000453:epidemiology / Q000209:etiology* / Q000503:physiopathology; D011795:Surveys and Questionnaires; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D004337:Drug Carriers; D018937:Hepatitis C Antibodies; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a